These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36673123)

  • 21. Predictability of early changes in derived neutrophil-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Lim JU; Kang HS; Yeo CD; Kim JS; Park CK; Kim JW; Kim SJ; Lee SH
    J Thorac Dis; 2021 May; 13(5):2824-2832. PubMed ID: 34164174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
    Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
    Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Outcomes and Prognostic Factors of Salvage Stereotactic Body Radiotherapy for Post-Surgical Thoracic Oligo-Recurrence/Metastasis of Non-Small-Cell Lung Cancer.
    Li WC; Wang Z; Gao J; Zhou H; Li J; Zhu XX
    Cancer Manag Res; 2021; 13():1887-1896. PubMed ID: 33654433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stereotactic body radiotherapy or stereotactic ablative radiotherapy versus surgery for patients with T1-3N0M0 non-small cell lung cancer: a systematic review and meta-analysis.
    Li M; Yang X; Chen Y; Yang X; Dai X; Sun F; Zhang L; Zhan C; Feng M; Wang Q
    Onco Targets Ther; 2017; 10():2885-2892. PubMed ID: 28652770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience.
    Luo H; Ge H; Cui Y; Zhang J; Fan R; Zheng A; Zheng X; Sun Y
    J Cancer; 2018; 9(1):182-188. PubMed ID: 29290784
    [No Abstract]   [Full Text] [Related]  

  • 27. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
    Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
    Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early-Stage Non-Small Cell Lung Cancer Stereotactic Body Radiation Therapy Outcomes in a Single Institution.
    Doupnik NP; Hirmiz K; Hussein AA; Agapito J; Pan M
    Cureus; 2022 Feb; 14(2):e21878. PubMed ID: 35273848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy.
    Öjlert ÅK; Nebdal D; Lund-Iversen M; Åstrøm Ellefsen R; Brustugun OT; Gran JM; Halvorsen AR; Helland Å
    Acta Oncol; 2021 Feb; 60(2):149-156. PubMed ID: 33356733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patients.
    Hu H; Yao X; Xie X; Wu X; Zheng C; Xia W; Ma S
    World J Urol; 2017 Feb; 35(2):261-270. PubMed ID: 27255479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
    Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B
    JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of pre-treatment C-reactive protein level and skeletal muscle mass on outcomes after stereotactic body radiotherapy for T1N0M0 non-small cell lung cancer: a supplementary analysis of the Japan Clinical Oncology Group study JCOG0403.
    Matsuo Y; Nagata Y; Wakabayashi M; Ishikura S; Onishi H; Kokubo M; Karasawa K; Shioyama Y; Onimaru R; Hiraoka M
    J Radiat Res; 2021 Sep; 62(5):901-909. PubMed ID: 34350956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response criteria in solid tumors (PERCIST/RECIST) and SUV
    Pierson C; Grinchak T; Sokolovic C; Holland B; Parent T; Bowling M; Arastu H; Walker P; Ju A
    Radiat Oncol; 2018 Feb; 13(1):34. PubMed ID: 29486779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer.
    Li C; Wang L; Wu Q; Zhao J; Yi F; Xu J; Wei Y; Zhang W
    Medicine (Baltimore); 2020 Aug; 99(34):e21715. PubMed ID: 32846789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies.
    Grenader T; Nash S; Plotkin Y; Furuse J; Mizuno N; Okusaka T; Wasan H; Valle J; Bridgewater J
    Ann Oncol; 2015 Sep; 26(9):1910-1916. PubMed ID: 26037798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of an inflammatory index for patients with metastatic castration-resistant prostate cancer.
    Yamada Y; Sakamoto S; Rii J; Yamamoto S; Kamada S; Imamura Y; Nakamura K; Komiya A; Nakatsu H; Ichikawa T
    Prostate; 2020 May; 80(7):559-569. PubMed ID: 32134137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis.
    Scotti V; Bruni A; Francolini G; Perna M; Vasilyeva P; Loi M; Simontacchi G; Viggiano D; Lanfranchi B; Gonfiotti A; Topulli J; Olmetto E; Maragna V; Ferrari K; Bonti V; Comin C; Balduzzi S; D'Amico R; Lohr F; Voltolini L; Livi L
    Clin Lung Cancer; 2019 Jan; 20(1):e53-e61. PubMed ID: 30348595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.